Arrowhead Pharmaceuticals

ARWR | NASDAQ | 0 Followers

$15.50

-1.27%

-$0.20

Overview Metrics Financials

Fair Price

$25.74

Undervalued by 5.0%

To display the fair price of a share, you need to be a member of Bulios Black.

Company Quality

Profitability Score

17/100

Solvency Score

59/100

Dividends

Dividends data currently unavailable.

Earnings

8/6/2025

in 48 days

Revenue est.

EPS est.

My Notes

You haven't added any notes for this stock yet. Use this space to record your insights or strategies.

Profile

Healthcare

Sector

Biotechnology

Industry

Dr. Christopher R. Anzalone Ph.D.

CEO

609

Employees

Pasadena

Headquarters

Country

Arrowhead Pharmaceuticals is a U.S.-based biotechnology company focused on developing innovative therapies targeting genetic diseases. The company is particularly known for its advanced RNA interference (RNAi) technology, which enables the "turning off" or regulation of genes associated with various diseases. Arrowhead Pharmaceuticals focuses on developing drugs for the treatment of rare and chronic conditions, including genetic disorders, viral infections, and cardiovascular diseases, aiming to improve treatment outcomes and the quality of life for patients.

Key Metrics TTM

Valuation

Market cap.

$2.1B

Enterprise Value

$2B

Price to Earnings

-14.11

Price to Sales

3.93

Price to Book

3.03

Price to Cash Flow

-3.74

Profitability

Return on Assets

-9.31%

Return on Equity

-46.83%

Return on Invested Capital

-84.54%

Gross Margin

98.16%

Operating Margin

-21.74%

Net Margin

-26.88%

Liquidity

Quick Ratio

4.29

Current Ratio

4.29

Cash Ratio

4.29

Inventory Turnover

0.00

Asset Turnover

0.35

Total Liabilities

$889M

Solvency

Debt to Assets

0.00

Debt to Equity

N/A

Interest Coverage

-1.88

Equity Ratio

0.43

Long-term Debt to Cap.

0.00

Altman Z-Score

1.72

Performance

Earnings Waterfall

Debt level and coverage

Earnings

Feed

There are no posts to show right now.